Objective: Blunt trauma patients may present with similar demographics and injury severity yet differ with regard to survival. We hypothesized that this divergence was due to different trajectories of systemic inflammation and utilized computational analyses to define these differences. Design: Retrospective clinical study and experimental study in mice. Setting: Level 1 trauma center and experimental laboratory. Patients: From a cohort of 493 victims of blunt trauma, we conducted a pairwise, retrospective, case-control study of patients who survived over 24 hours but ultimately died (nonsurvivors; n = 19) and patients who, after ICU admission, went on to be discharged(survivors; n = 19). Interventions: None in patients. Neutralizing anti-interleukin-17A antibody in mice. Measurements and Main Results: Data on systemic inflammatory mediators assessed within the first 24 hours and over 7 days were analyzed with computational modeling to infer dynamic networks of inflammation. Network density among inflammatory mediators in nonsurvivors increased in parallel with organ dysfunction scores over 7 days, suggesting the presence of early, self-sustaining, pathologic inflammation involving high-mobility group protein B1, interleukin-23, and the Th17 pathway. Survivors demonstrated a pattern commensurate with a self-resolving, predominantly lymphoid response, including higher levels of the reparative cytokine interleukin-22. Mice subjected to trauma/hemorrhage exhibited reduced organ damage when treated with anti-interleukin-17A. Conclusions: Variable type 17 immune responses are hallmarks of organ damage, survival, and mortality after blunt trauma and suggest a lymphoid cell-based switch from self-resolving to self-sustaining inflammation. (Crit Care Med 2016; 44:e1074-e1081) 
with seemingly identical injuries can have markedly divergent clinical trajectories.
We and others have hypothesized that differential initial conditions and dynamic trajectories of injury-induced systemic inflammation underlie some of the variability in clinical outcomes (2) (3) (4) . Mechanical injuries result in the production and release of damage-associated molecular patterns (DAMPs) and downstream proand anti-inflammatory chemokines, cytokines, free radicals, and cellular changes within the injured tissue, extending into the circulatory system and affecting distant organs and tissues (2, 5) . Highly regulated inflammation leads to resolution, reestablishment of homeostasis, and tissue repair. However, a self-sustaining, seemingly irreversible inflammatory process can also be set in motion, driving a systemic, malignant pathobiology across multiple organ systems (6) . Despite progress correlating circulating inflammatory mediators with poor clinical trajectories and fatal outcomes (7) (8) (9) (10) , there are currently no validated inflammation biomarkers that predict mortality nor Food and Drug Administration-approved drugs targeting trauma-induced inflammation (11) .
In this study, we hypothesized that because of heretofore unrecognized preexisting differences, some trauma victims would respond to traumatic injury by elaborating a complex, dynamic inflammatory response that drives multiple organ dysfunction and leads to death, whereas otherwise quite similarly injured patients would exhibit a different response that does not lead to worsened organ dysfunction. We further hypothesized that these inflammatory responses could be characterized in the form of differential dynamic networks, in which the mediators would be represented as nodes and the interactions among them would be represented as edges connecting them. The blunt trauma setting is particularly advantageous for this type of dynamic analysis, as it affords the study an initiating time point from which the course of inflammation can be observed. Here, we report an early divergence between inflammatory networks that characterize survivors and nonsurvivors of blunt trauma in a manner that closely parallels their divergent trajectories of organ failure. Our analysis also implicates differential engagement of lymphocyte subsets in driving inflammatory stability versus mortality after trauma.
MATERIALS AND METHODS

Patient Enrollment and Study Design
We utilized a patient cohort of 493 blunt trauma victims reported previously (12) (13) (14) (15) . From the 493 patients enrolled, we retrospectively performed a stringent, pairwise, case-control study with 1:1 matching of nonsurvivors to a subcohort of survivors according to age, sex, mechanism of injury, traumatized body region, injury severity, initial blood pressure, course of treatment, and incidence of nosocomial infection. Details of the stringent case identification are provided in Supplemental Digital Content-Text 1 (Supplemental Digital Content 1, http://links.lww.com/CCM/B962).
Experimental Hemorrhagic Shock/Trauma (HS/T) and Neutralization of Interleukin (IL)-17A
Experimental procedures were carried out in accordance with all regulations regarding the care and use of experimental animals as published by the National Institutes of Health. A previously published experimental paradigm of combined HS/T model (16) was utilized as described in Supplemental Digital Content-Text 2 (Supplemental Digital Content 2, http://links.lww.com/CCM/B963). Of note, these mouse studies were conducted in mice that are young relative to the human cohort. Plasma was used for quantification of IL-17A/F and alanine aminotransferase (ALT). At 6 hours after HS/T, a group of mice (n = 6) received 100 µg of neutralizing monoclonal anti-IL-17 antibody (clone 17F3; Bio X Cell, West Lebanon, NH) diluted in phosphate-buffered saline to a total volume of 100 µL via intraperitoneal injection 12 hours prior to HS/T and 100 µg at the time of resuscitation. A control group (n = 6) received an injection of PBS in 100 µL 12 hours before HS/T and 100 µL at the time of resuscitation.
Analysis of Inflammation and Organ Damage Biomarkers in Human and Mouse Samples
A Luminex 100 IS analyzer (Luminex, Austin, TX) and Human Cytokine/Chemokine or Human Th17 MILLIPLEX Panel kit (Millipore, Billerica, MA) were used to measure plasma levels of IL-1β, IL-2, soluble IL-2 receptor-α (sIL-2Rα), IL-4, IL-5, IL-6, IL-7, IL-8 (chemokine [C-C motif] ligand [CCL] 8), IL-10, IL-13, IL-15, IL-17, IL-21, IL-22, IL-23, interferon (IFN)-γ, IFN-γ inducible protein-10 (chemokine [C-X-C motif] ligand [CXCL] 10), monokine induced by gamma IFN (MIG; CXCL9), macrophage inflammatory protein (MIP)-1α (CCL3), MIP-1β (CCL4), monocyte chemotactic protein (MCP)-1 (CCL2), granulocyte-macrophage colony stimulating factor (GM-CSF), eotaxin (CCL11), and tumor necrosis factor (TNF)-α. High-mobility group protein B1 (HMGB1) measurement was performed using enzyme-linked immunosorbent assay (ELISA) (Shino-Test, Kanagawa, Japan; distributed by IBL international, Toronto, ON, Canada). NO 2 -/NO 3 levels were measured by a Griess Reagent colorimetric assay (Cayman Chemical, Ann Arbor, MI). To establish a baseline, inflammation biomarker data were obtained from 12 healthy volunteers (mean age, 46 ± 2.1; eight males and four females) with no history of recent trauma, infections, or existing comorbidities. Mouse IL-17A/F was quantified by ELISA (R&D, Minneapolis, MN). Mouse ALT levels were assayed using a Dry-Chem Veterinary Chemistry Analyzer (HESKA, Loveland, CO; slides from Fujifilm, Asaka-shi Saitama, Japan).
Statistical Analysis
All data were analyzed using SigmaPlot 11 software (Systat Software, San Jose, CA). Statistical difference between survivors and nonsurvivors was determined by either Student t test or chisquare test as appropriate. Group-time interaction of plasma inflammatory mediators' levels between survivors and nonsurvivors was determined by two-way analysis of variance and quantified by area under the curve (AUC) using the mean values for each time point, and then calculating nonsurvivors/survivors AUC fold change. Spearman rank correlation was calculated by using MATLAB (MathWorks, Natick, MA). P value less than 0.05 was considered statistically significant for all analyses. 
Computational Methods: Dynamic Bayesian Network (DyBN) and Dynamic Network Analysis (DyNA)
We carried out DyBN and DyNA inferences as previously described by our group (13, 14, 17, 18 
RESULTS
Stringently Matched Survivors and Nonsurvivors Diverge in Clinical Outcomes and Inflammatory Mediators
The stringent case identification resulted in a final subcohort of 19 nonsurvivors (mean age, 58.8 ± 4.5; Injury Severity Score [ISS], 23.3 ± 2.1; Glasgow Coma Scale [GCS], 10.6 ± 1.8), with a male-to-female ratio of 16:3. A highly matched population of 19 survivors (mean age: 59.0 ± 3.0, p = 0.977; ISS: 23.4 ± 2.0, p = 0.912; GCS: 13.9 ± 0.73, p = 0.236), with an equivalent male-to-female ratio, served as a control subcohort (Supplemental Table 1 Despite this homogeneity between subcohorts, survivors and nonsurvivors experienced different degrees of organ dysfunction (Fig. 1A) . The survivor cohort exhibited a slight decrease in Marshall multiple organ dysfunction (MOD) score over 7 days. The nonsurvivors exhibited later-onset and increasing multiple organ dysfunction, with statistically elevated and sustained multiple organ failure (MOD score, ≥ 5) at approximately day 5.
Differential Networks of Systemic Inflammation Implicate HMGB1, Chemokines, and Type 17 Cell Pathways
The divergent trajectories of organ dysfunction seen in survivors and nonsurvivors led us to hypothesize that these subcohorts would exhibit different time courses of systemic inflammation. Indeed, nonsurvivors exhibited significantly elevated circulating levels of HMGB1 (p < 0.001), IL-8 (p = 0.006), MIG (p = 0.008), eotaxin (p = 0.023), and MIP-1β (p = 0.049). In contrast, circulating IL-22 (p = 0.028) was significantly higher in survivors versus nonsurvivors (complete data available in Supplemental We next sought to determine, in a more granular fashion, the and Appendix A, Supplemental Digital Content 11, http:// links.lww.com/CCM/B972). One metric that can be used to assess the degree of interconnection is network complexity (18) , which remained low and stable in survivors, whereas increasing progressively in nonsurvivors. Notably, network complexity indices closely paralleled the respective clinical trajectories of organ dysfunction (Fig. 1B) . Inferred dynamic networks in the survivors group predominantly involved cytokines associated with T cell activation (IL-4, IL-5, IL-13, IL-17A, IL-22, IL-23, and sIL-2Rα), discernible as early as 24 hours ( Fig. 2A) . In survivors, DyNA suggested the early formation of relatively sparse networks of interaction involving predominantly T cell-related (lymphoid) mediators, which persisted over the 7-day course. In contrast, the dynamic networks of nonsurvivors were characterized by interconnections among both innate immune mediators (eotaxin, IL-8, MIP-1α, MIP-1β, IL-1β, TNF-α, IFN-α, and IFN-γ) and lymphoid mediators (IL-2, IL-4, IL-5, IL-7, IL-13, IL-17A, IL-21, IL-22, and IL-23), starting early postinjury. These networks evolved into much larger, innate immune-dominant networks after 72 hours (Fig. 2B) . DyNA also inferred a nearly ubiquitous connection between IL-22 and IL-23 over 7 days in both survivors and nonsurvivors. However, IL-21 was only discernable in the nonsurvivor networks. The DyBN-generated hypothesis associating HMGB1 with IL-23, the presence of IL-17A, IL-21, IL-22, and IL-23 in early time intervals in DyNA, and the known role of IL-23 in stabilizing Th17 cell populations (19) and group 3 innate lymphoid cells (ILC3) (20) led us explore the possibility of an early type 17 immune response to trauma. Lee et al (21) have described a subpopulation of type 17 cells known as "pathogenic Th17 cells" that, in addition to expressing IL-17A, up-regulate GM-CSF and down-regulate IL-10 in a manner that is potentiated by IL-23 (21) . In line with this characterization, plasma IL-17A in nonsurvivors was correlated positively with circulating GM-CSF (r = 0.414; p = 0.009) and negatively with circulating IL-10 (r = -0.408; p = 0.007), whereas IL-17A in survivors presented neither positive nor negative correlations with GM-CSF nor IL-10 (p = 0.810 and p = 0.489, respectively) (Fig. 3) . We next hypothesized that early activation of the type 17 cells could drive morbidity. In support of this hypothesis, mice subjected to experimental HS/T had elevated levels of IL-17A ( Fig. 4A ) at 6-hour posttrauma, which declined subsequently. In support of a pathologic role for IL-17, mice treated with neutralizing anti-IL-17 antibody exhibited reduced circulating IL-17A (Fig. 4B) as well as a nearly 70% reduction in levels of ALT (a marker of organ dysfunction) (Fig. 4C) .
DISCUSSION
We sought to utilize stringently matched cohorts to reduce patient-to-patient variability combined with computational analytics to address the complexity of postinjury inflammation. By comparing highly matched cohorts of survivors and nonsurvivors of blunt trauma, we were able to define two disparate dynamic networks of systemic inflammation predictive of the unequivocal endpoints of posttraumatic outcomes-life and death. Several key observations were derived from this approach, some of which support earlier notions about how inflammation may drive outcomes posttrauma, and others that appear to set a new paradigm more in common with chronic inflammatory conditions than with the acute inflammation typically associated with trauma.
The most evident insight is that injury severity alone does not appear to be the sole driver of mortality after blunt trauma. It is important to note that in this study, patients presenting to the emergency department with a predicted survival of less than 24 hours were excluded from the study because most patients dying during this time period die of uncontrolled hemorrhage or devastating head injury (2) . Thus, we studied patients who survived the initial mechanical insult yet, because of underlying and undefined genetic, epigenetic, and pathophysiologic reasons, went on to experience a higher degree of organ dysfunction and ultimately die. This suggests that the simplistic paradigm of increasing severity of injury leading ultimately to death may need to be replaced with one in which underlying and perhaps preexisting inflammatory conditions contribute to the lethal outcome as much as, or more than, the magnitude of the injury alone. Notably, we calculated injury severity using the ISS scoring system, which is a mathematical aggregation of body region-specific injuries and a well-accepted method of stratifying the degree of injury for patients after trauma. Although this scoring system was designed to quantify the injury burden postdischarge and has been improved subsequently to become more predictive of clinical outcomes of broad groups of trauma patients especially at the extremes of injury severity, it is incapable of correlating injury severity with individual outcomes (22, 23) . Also, it is possible that there were occult differences in injury severity between survivors and nonsurvivors.
A key insight from the in silico inference of dynamic complexity relates to the early bifurcation of well-regulated inflammatory processes in survivors versus an unregulated, self-sustaining systemic inflammatory response in those who die. Importantly, these dynamic inflammatory networks mimic the clinical trajectories of organ dysfunction over 7 days in both survivors and nonsurvivors. Based on network analyses, this inflammatory bifurcation involved both well-appreciated innate immune pathways and lymphoid pathways more typically associated with chronic inflammation.
Within hours after the traumatic insult, we found supranormal levels of HMGB1 in both survivors and nonsurvivors. The early and important role of HMGB1 and similar Figure 3 . A pathogenic Th17 phenotype is associated with nonsurvival. Trauma patients were recruited after institutional review board approval and informed consent. Plasma was obtained at multiple time points and analyzed for the presence of 27 inflammatory mediators in highly matched subcohorts of survivors and nonsurvivors, and the data were subjected to Bootstrapped Spearman rank correlation as described in the "Materials and Methods. " This analysis suggests a positive correlation between interleukin (IL)-17A and granulocyte-macrophage colony stimulating factor (GM-CSF) and a negative correlation between IL-17A and IL-10, consistent with a pathogenic Th17 phenotype. No significant correlation was found among these mediators in the survivors' subcohort. The shaded area in pink represents the 95% CI.
Critical Care Medicine www.ccmjournal.org e1079 prototypical DAMPs in response to trauma is well documented in the literature (9, 24) , and this finding has served to support the putative role of DAMPS as activators and propagators of early innate immune pathways in which chemokines play a key role. Our dynamic Bayesian inferences in both survivors and nonsurvivors suggested that the chemokines MCP-1/CCL2 and MIG/CXCL9 are outputs downstream of HMGB1, validating the proposed sequence of events as well as work that places both MCP-1 and MIG as important drivers of posttraumatic inflammation (10, 14) .
Our in silico analyses also unmasked a relationship between HMGB1 and a type 17 cell immune response as early as 24 hours among nonsurvivors (for details on type 17 cells, see Supplemental Digital Content-Text 5, Supplemental Digital Content 14, http://links.lww.com/CCM/B975). Over the past decade, IL-17 and IL-23 have been identified as important players in numerous chronic autoimmune inflammatory diseases (19, (25) (26) (27) . A link between HMGB1 and the IL-23-Th17 axis via toll-like receptor signaling was also established in experimental hemorrhagic shock (28) . However, to our knowledge, this is the first study to link DAMPs, chemokines, and the IL-23-Th17 immune axis with acute systemic inflammation after blunt trauma in humans. Furthermore, DyBN inference in the survivor cohort places IL-6 and IL-22, both of which are characteristic cytokines of type 17 immune responses, downstream of HMGB1 (29, 30) . The cytokine IL-22 was the only statistically significantly elevated mediator in the survivor cohort and was ubiquitously present in DyBN and DyNA inflammatory networks. Innate-derived IL-22 has well-established roles in the protection and repair of epithelial tissue, particularly in the gut (31, 32) . Therefore, it is tempting to speculate that the higher IL-22 levels in survivors are mechanistically linked to resolution and survival. Along with IL-17A and GM-CSF, IL-22 is a signature cytokine of a type 17 immune response and is produced by both Th17 and ILC3 (19, 20) . Although our data suggest evidence for both ILC and Th17 responses, we cannot yet conclusively determine the cellular source of IL-22 in human blunt trauma.
Considerable work on type 17 cell subsets has broadly divided Th17 cells into two categories: nonpathogenic Th17 cells that express both IL-17 and IL-10 (29) and highly inflammatory, pathogenic Th17 cells that up-regulate GM-CSF and down-regulate host-protective IL-10 (21). We found a strong correlation between IL-17A and GM-CSF and a strong negative correlation between IL-17A and IL-10 in nonsurvivors but not in survivors, leading us to hypothesize that pathogenic Th17 cells are associated with nonsurvival after trauma. In line with the characterization, early administration of an anti-IL-17 antibody in mice proved efficacious in reducing organ dysfunction in the context of experimental HS/T, although the fact that the mice are relatively young compared with the human cohort is a limitation of that experiment.
DyNAs also elucidated that a core network comprised of IL-17A, IL-4, and sIL-2Rα is associated with survival, consistently present and sparsely connected with MIP-1α/CCL3 over the first 7-day postinjury. A supplementary DyNA inference carried out on all 472 survivors from the overall 493 patient cohort also confirms the presence of a network involving connections among IL-17A, IL-4, and sIL-2Rα consistently after 72 hours (Supplemental Fig. 6 , Supplemental Digital Content 15, http://links.lww.com/CCM/B976; legend, Supplemental Digital Content 16, http://links.lww.com/CCM/B977).We hypothesize that this is a relatively beneficial response network that reflects lymphocyte (Th17, Th2, and Treg) diversity and a well-regulated, nonpathogenic Th17 response. This hypothesis is supported by considerable literature that cites the cross-regulatory effects of IL-4, IL-17, and sIL-2Rα on Th2, Th17, and Treg populations (33) (34) (35) (36) . Indeed, a recent study reports that the transdifferentiation of Th17 cells to express Treg and Th2 regulatory phenotypes is critical for the resolution of inflammation (37) . MIP-1α/CCL3 is peripherally involved in the inflammatory networks of the matched subcohorts and consistently connected to the core IL-17A, IL-4, and sIL-2Rα in the supplementary analysis. A recent study cites the increased expression of CCL3 in a pathogenic Th17 mouse model of autoimmunity (38) . Considering the overall low mortality rate that characterizes civilian blunt trauma, there remains a need for larger, multicenter studies utilizing flow cytometry and analyses of key transcription factor expression (39-41) to validate any role for pathogenic Th17 cells or other cell types (e.g., ILCs) (19, 20) in the pathophysiology associated with trauma mortality.
We therefore hypothesize the presence of a decisive "tipping point" (42) between an innate-and lymphoid-dominant response that occurs between 24 and 72 hours after injury in nonsurvivors ( Fig. 5) . Unlike the relatively stable, lymphoiddominant inflammatory networks characteristic of survivors, the dynamic networks in nonsurvivors are characterized by sparsely connected innate and lymphoid mediators in the first 24 hours, which ultimately develop into highly connected, self-sustaining networks by 72 hours. Notably, a recent study attributes three time-dependent transcriptional phases to the transition from naive-like cells to Th17 cells after T cell receptor stimulation: induction (up to 4 hr); onset of phenotype and amplification (4-20 hr); and stabilization and IL-23 signaling (20-72 hr) (43) . In support of the latter study, we observed a predisposition to amplify a pathogenic or nonpathogenic Th17 phenotype (0-24 hr postinjury) along with a putative "tipping point" period (24-72 hr postinjury) in which the inflammatory response becomes either self-resolving or self-sustaining in nature. This period from 24 to 72 hours after trauma may actually determine the trajectory toward organ failure and nosocomial infection.
Expanding on the existing paradigm of simultaneously increased activation of innate immune pathways and decreased activation of adaptive immune pathways after trauma (5), we hypothesize the presence of an "inflammatory switch state" involving innate and lymphoid mediators (Fig. 5A ). In this paradigm, the magnitudes of pro-and anti-inflammatory responses remain a critical aspect in determining clinical outcomes. However, we hypothesize that the magnitude of the inflammatory response is either attenuated by a balanced lymphoid response or intensified by a self-sustaining, predominantly innate-mediated, response (Fig. 5B) . We predict that a wellbalanced lymphoid signature involves nonpathogenic Th17 cells and an adequate IL-22 response to injury that is commensurate with survival. In contrast, the early activation of a pathogenic Th17 phenotype is triggered when the balance between lymphocytes is tipped, leading to progressive organ failure and death. We further hypothesize that a given individual may be somehow predisposed for an innate-or a lymphoid-dominant response on traumatic insult, much like patients who have dysregulated Th17 responses are predisposed to develop chronic inflammatory disease-a predisposition that is likely controlled by a combination of many genetic and epigenetic factors, as well as age, sex, preexisting diseases, microbiome composition, etc. This hypothesis requires extensive validation in further clinical and preclinical paradigms of traumatic injury but holds the potential to drive a novel generation of diagnostic and therapeutic modalities.
CONCLUSIONS
Our data suggest that shortly after blunt trauma, and possibly because of preexisting factors, some patients proceed toward a path of self-sustaining inflammation and associated organ dysfunction, which culminates in death. Similarly, injured patients respond to the injury with a lower-grade, subthreshold inflammatory response associated with resolving organ dysfunction and eventual survival. This "inflammatory switch" may be triggered or regulated by variable type 17 immune responses. Figure 5 . Inflammatory switch state hypothesis. A hypothetical "inflammatory switch state, " involving innate and lymphoid mediators early on following trauma. In this paradigm, the magnitude of a pro-and anti-inflammatory response remains a critical aspect in determining clinical outcomes. A, A well-balanced lymphoid signature after traumatic injury involves Treg, Th2, and nonpathogenic Th17 (Th17 NP ) cells. In contrast, the early activation of a pathogenic Th17 (Th17 P ) phenotype is triggered when the balance between lymphocytes is tipped leading to an uncontrolled inflammatory cascade-much like the balance of lymphocytes is tipped in those predisposed to develop chronic inflammatory diseases. B, The severity of pro-and anti-inflammatory mediator involvement (represented horizontally in the x-axis) is either attenuated by a balanced lymphoid response or, conversely, exacerbated by a self-sustaining, predominantly innate-mediated response. Thus, this diagram represents the two major outcomes of these contrary inflammatory patterns: 1) a well-balanced lymphoid response leads to injury resolution and 2) a loss of lymphocyte regulation engages self-sustaining inflammation that impedes injury resolution. MODS = multiple organ dysfunction syndrome, NI = nosocomial infection.
